Help patients within the growing space of substance use disorders and mental health

Listen to the recorded teleconference, July 2, discussing the plans for commercialization of DTx in the US

Launch of deprexis® and vorvida® initiated in the US

Today the company announces the US launch of its scientifically proven digital therapies deprexis® and vorvida® has been initiated. The decision to accelerate the launch of the digital offering, also incl. OXD01, is based on the patient need for access to low-risk clinically-validated digital health devices during the ongoing COVID-19 pandemic and the recent FDA “Enforcement Policy” providing a fast pathway to market. The accelerated launch will increase investments and OPEX FY 2020 expects to be in the range of SEK 780-800 m.

Positive results from OX125 human PK study

JUNE 30, 2020 - Preliminary results for OX125 indicate extensive and rapid absorption across all formulations as well as good tolerability, supporting the viability of OX125 as a rescue medication for opioid overdose. OX125 could be an important addition to OX124 and the results underline the applicability of Orexo’s novel intranasal drug delivery platform.

With marks of wisdom she continues to inspire us all

Our colleague Geri Lynn Utter is, mildly spoken, the right person at the right place. As a child of parents who suffered from drug addiction, she, against all odds, became a doctor of psychology. A moving story depicted in her first book ”Mainlining Philly”. Today, in her role as Medical Science Liaison at Orexo, Geri plays a key role in raising awareness around addiction and mental health issues.